Comparative Assessment of the Use of Norepinephrine with Phenylephrine During Spinal Anaesthesia for Caesarean Birth

Md Imran Mehdi¹, Saurabh Arya², Poonam Verma³, Surendra Singh⁴

¹Assistant Professor, Department of Anaesthesiology and Critical Care, Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pardesh, India
²Junior Resident, Department of Anaesthesiology and Critical Care, Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pardesh, India
³Junior Resident, Department of Anaesthesiology and Critical Care, Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pardesh, India
⁴Professor, Department of Anaesthesiology and Critical Care, Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pardesh, India

Received: 05-07-2021 / Revised: 10-08-2021 / Accepted: 29-08-2021
Corresponding author: Dr. Md Imran Mehdi
Conflict of interest: Nil

Abstract

Aim: Norepinephrine versus phenylephrine for maintenance of blood pressure during spinal anaesthesia for caesarean delivery.

Methods: This prospective randomized, double blind controlled study conducted in the, Department of Anaesthesiology and critical care, Era’s Lucknow Medical college and Hospital, Lucknow, Uttar Pardesh, India, for 11 months. After written informed consent to participate in study, 100 patients of 18-32 years of age group, having singleton, full term pregnancy, American Society of anaesthesiologist physical status (ASA) II posted for elective caesarean section under spinal anaesthesia were included in the study.

Results: 100 patients were included in this study. Patient characteristics and surgical time were similar between the two groups. Both the drugs were able to maintain the systolic blood pressure following spinal anaesthesia throughout the surgery (p=0.37). In group N, no changes observed in CO while in group P, it decreased from 3 minutes to 15 minutes, with maximum fall after 5 minutes and then after maintained till the end of surgery (p<0.05). Comparing both the groups, CO remained less in patients with phenylephrine group than norepinephrine group for 3 to 15 minutes after spinal anaesthesia (p=0.016). Then after, it was comparable in both the groups. Requirement of total intermittent bolus doses were comparable (1.8± 0.74 vs 1.44 ±0.53) in both the groups (p=0.078). In group N, no difference in mean pulse rate was observed. While, in group P, significant decrease in mean pulse rate was observed from the preoperative value till the end of surgery (p<0.01). On inter group comparison, the mean pulse rate remained lower in group P as compared to group N from 1 min till 20 minutes, then after it was comparable between both the groups (p=0.001). Conclusion: Norepinephrine is as effective as phenylephrine for maintenance of blood pressure during spinal anaesthesia for caesarean delivery with stable cardiac output and heart rate. It can be used as an alternative vasopressor to phenylephrine for managing intra operative hypotension during spinal anaesthesia for caesarean delivery.

Keywords: caesarean delivery, phenylephrine, vasopressor

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative
Introduction

Subarachnoid block (SAB) is the technique of choice for elective caesarean section; however, it does result in hypotension in the vast majority of parturients if not actively prevented.[1] Thus, the routine use of vasopressors has been highly recommended for preventing post-spinal hypotension in parturients undergoing caesarean delivery. Phenylephrine (PE), a potent alpha-adrenergic receptor agonist, is the current gold standard vasopressor recommended for the prevention and treatment of maternal spinal-induced hypotension in parturients undergoing caesarean section under SAB. PE causes slowing of maternal heart rate (HR) and corresponding decrease in cardiac output (CO).[2] There have been growing concerns that the reflex slowing of heart rate, a surrogate marker of CO, may result in compromised uteroplacental perfusion, potentially adversely affecting a compromised foetus.[3] Norepinephrine (NE), a potent alpha-adrenergic receptor agonist with relatively weak agonistic activity at beta-adrenergic receptors, is being considered as an alternative to PE as it causes lesser degree of bradycardia with minimal decrease in cardiac output due to its mild beta-agonist activity.[4] The safety profile of norepinephrine for foetus is another concern but it does not readily cross the placenta.[5,6]

This study compared the effectiveness of prophylactic and treatment boluses of norepinephrine and phenylephrine to maintain systolic blood pressure at or above 80% of baseline value during spinal anaesthesia for caesarean delivery with the primary aim to compare the cardiac output. The secondary aims were total doses of study drug required, neonatal outcome and perioperative complications.

Material and methods

This prospective randomized, double blind controlled study conducted in the, Department of Anaesthesiology and critical care, Era’s Lucknow Medical college and Hospital, Lucknow, Uttar Pardesh, India, for 11 months, after taking the approval of the protocol review committee and institutional ethics committee. After written informed consent to participate in study, 100 patients of 18-32 years of age group, having singleton, full term pregnancy, American Society of anaesthesiologist physical status (ASA) II posted for elective caesarean section under spinal anaesthesia were included in the study. Exclusion criteria included patients with contraindications to spinal anaesthesia, allergy to study medication, known foetal abnormality, hypertension, arrhythmia and morbid obesity. Patients were randomly assigned to two groups [Group N- norepinephrine 6 µg (Adrenor, 2mg/ml, Samarth) and Group P – phenylephrine 100 µg (Phenpres, 10mg/ml, Neon)] by using computer generated random numbers and the assignment was sealed in opaque envelopes. For ensuring blinding, identical 10 ml coded syringes of drugs with 1ml being required study dose (100µg/ml or 6µg/ml), will be prepared under the guidance of consultant by one of the fellows, who will not participate in performing subarachnoid block or recording the outcome during intraoperative and postoperative periods. The syringe will be labelled as “study drug.” The patient and the observer will be blinded to the content of the drugs.

All participants were kept nil per oral for 6 hours prior to operation. On arrival to the operation theatre, 18gauge intravenous canula was accessed and positioned supine with left lateral tilt. Multipara monitor, Life-Scope (Nihon-Kohden, Tokyo, Japan) was attached and baseline heart rate (HR), systolic blood pressure (SBP), oxygen saturation (SpO2), electrocardiogram (ECG), non- invasive cardiac output (CO)
recorded. This monitor gives estimated continuous cardiac output (esCCO) non-invasively using pulse wave transit time (PWTT) technology which is defined as the time from the ECG R-wave peak to the pulse wave rise point. All parturient were premedicated with intravenous ranitidine 0.5-1 mg/kg and ondansetron 0.08 mg/kg. They were preloaded with ringer lactate solution 10ml/kg 15 min before induction. Spinal anaesthesia was given in L3–L4 intervertebral space under all aseptic precaution, in lateral decubitus position. After confirmation of free CSF flow, bupivacaine (0.5%) 2 ml was injected intrathecally. Monitoring was started immediately on making the patient supine and prophylactic bolus dose of study drug was given intravenously. Non-invasive blood pressure and cardiac output monitoring were started immediately after intrathecal injection, and the automatic cycling time was set to 2 minutes until delivery and then every 15 minutes till the end of surgery. Heart rate was recorded at the time of completion of each blood pressure measurement. ECG and SpO₂ were measured continuously.

Whenever there was fall in blood pressure (fall in SBP > 20% of baseline value or SBP < 90 mm Hg), the study drug dose was repeated and at the end, total dose requirement was calculated. Intra operative bradycardia (HR<50beats/min) was treated with atropine 0.6 mg intravenously. Nausea, vomiting and other maternal undesired effects were noted and managed accordingly. Apgar score was assessed for neonatal outcome and noted down at 1, 5 and 10 minutes after delivery.

Parturient who had failure of spinal anaesthesia or required supplementation of general anaesthesia or developed post-partum haemorrhage intraoperatively, were excluded from the study.

**Results**

100 patients were included in this study. Patient characteristics and surgical time were similar between the two groups. (Table1) Both the drugs were able to maintain the systolic blood pressure following spinal anaesthesia throughout the surgery (p=0.37). In group N, no changes observed in CO while in group P, it decreased from 3 minutes to 15 minutes, with maximum fall after 5 minutes and then after maintained till the end of surgery (p<0.05). Comparing both the groups, CO remained less in patients with phentylephrine group than norepinephrine group for 3 to 15 minutes after spinal anaesthesia (p=0.016). Then after, it was comparable in both the groups. Requirement of total intermittent bolus doses were comparable (1.8± 0.74 vs 1.44 ±0.53) in both the groups (p=0.078). (Table 1) In group N, no difference in mean pulse rate was observed. While, in group P, significant decrease in mean pulse rate was observed from the preoperative value till the end of surgery (p<0.01). On inter group comparison, the mean pulse rate remained lower in group P as compared to group N from 1 min till 20 minutes, then after it was comparable between both the groups (p=0.001). Apgar score of neonates at 1, 5 and 10 minutes were >7 in all cases in both the groups (p>0.05). (Table1) In group N, not a single patient developed bradycardia, whereas in group P, bradycardia was observed in 8 patients (p=0.021). The incidences of nausea/vomiting were comparable between the two groups. No other maternal perioperative complications were observed in both the groups. (Table1)
Table 1: Demographic data, bolus dose requirements, APGAR score and complications

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group N</th>
<th>Group P</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>28.04 ± 3.13</td>
<td>27.8 ± 3.12</td>
<td>1.2</td>
</tr>
<tr>
<td>Weight (Kg)</td>
<td>62.14 ±4.65</td>
<td>62.03 ±5.07</td>
<td>.79</td>
</tr>
<tr>
<td>Height (cm) Block Height</td>
<td>155.48 ± 3.82</td>
<td>156.62 ± 4.05</td>
<td>0.07</td>
</tr>
<tr>
<td>Duration of surgery (min)</td>
<td>46.66 ±5.49</td>
<td>46.16 ±5.99</td>
<td>0.70</td>
</tr>
<tr>
<td>No. of bolus doses</td>
<td>1.8± 0.74</td>
<td>1.44 ±0.53</td>
<td>0.078</td>
</tr>
<tr>
<td>APGAR Score at 1/5/10 min</td>
<td>7.63±0.55/7.96±0.55/8.63±0.49</td>
<td>7.63±0.49/8.13±0.57/8.92±0.49</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Bradycardia</td>
<td>0</td>
<td>8</td>
<td>0.021</td>
</tr>
<tr>
<td>Nausea/Vomiting</td>
<td>5 (10%)</td>
<td>3 (6%)</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Discussion

Both norepinephrine and phenylephrine, maintained blood pressure following spinal anaesthesia, but it was associated with fall in CO from 3 minutes till 15 minutes with highest fall at 5 minutes after spinal anaesthesia and with episodes of bradycardia in patients with phenylephrine group. Meanwhile, CO and HR were well maintained in patients with norepinephrine group. Uteroplacental blood flow is not auto regulated but directly coupled to maternal blood pressure, maternal hypotension must be treated immediately to avoid risk of foetal acidosis. Use of vasopressors, given their arterial vessel constriction property, is rational and advocated to rescue spinal anaesthesia induced hypotension. Being pure α adrenergic agonist, arteriolar vasoconstriction due to phenylephrine increases systemic vascular resistance (SVR) and often causing baroreceptor mediated bradycardia associated with decreased CO.[7,8] In capacitance vessels, such vasoconstriction may increase venous return, however simultaneous increase in venous resistance limits venous return to the heart.[7,9] Norepinephrine having strong α- adrenergic agonist activity and a mild β-adrenergic agonism, is routinely used to treat anaesthesia-induced vasodilatation by increasing SVR as often accompanied by stable CO and HR. Norepinephrine acts on β1 receptors in the myocardium which results into increase in contractility and HR leading to effective treatment of hypotension with preservation of CO. Though, direct α1 stimulation produces intense vasoconstriction with a resultant increase in SVR, venous return to the heart is increased via veno constriction due to stimulation of venous α1 receptors with norepinephrine.[10]

We used non-invasive CO monitoring based on esCCO measurement system. It is reliable and having good CO measurement accuracy equivalent to CO measured by pulmonary artery catheter.[11] According to literature, apparently the CO and uteroplacental perfusion can’t be accurately judged by monitoring of blood pressure alone. Therefore, ideal haemodynamic for caesarean delivery should be aiming for both maternal and foetal well-being through maintenance of blood pressure to ensure adequate flow through the low resistance uteroplacental unit, also without compromising the CO which is a key to O₂ delivery.[10] Studies have denoted similar maternal and foetal outcome using norepinephrine and phenylephrine including similar umbilical blood gas values in healthy parturient.[6,10] Future research is required to demonstrate whether greater
uteroplacental blood flow and oxygen delivery is associated with the use of norepinephrine compared to phenylephrine, particularly in conditions of compromised cardiac functions or uteroplacental perfusion, like preeclampsia or intrauterine growth retardation.

In both the groups, Apgar score of all neonates remained >7. Due to breakdown of catecholamines by placenta, both the vasopressor drugs do not rapidly cross the placenta. Studies demonstrated higher foetal pH with the use of phenylephrine compared to ephedrine.[12-16] Reduced foetal catecholamine level with the use of norepinephrine compared to phenylephrine, eliminates possible stimulation of foetal metabolism and acidaemia regularly seen with ephedrine.[6,7]

In our study, both the vasopressor drugs were administered by bolus dose. Infusion regimen requires either smart pumps or more physician intervention as well as a bit more time consuming. Bolus dose administration is easy to execute and clinically practice. Most of the clinicians favour the use of intermittent boluses rather than infusions.[10,17,18] Ngan Kee et al. used closed loop computer- controlled infusions to deliver both the vasopressor drugs which possibly can reduce bias that might emerge with manual infusion.[6] Work in future required to evaluate the efficacy of norepinephrine given by manually controlled infusion and intermittent boluses in obstetric patients.

We decided to give prophylactic dose of vasopressor immediately after giving spinal anaesthesia as recent studies suggested increasing the SVR as a better approach to prevent haemodynamic instability after spinal anaesthesia.[10,19] Requirement of bolus doses were similar in both the groups. Nitu Putheneettil observed less requirement of bolus doses with norepinephrine compared to phenylephrine group.[18]

Different potency ratio of norepinephrine to phenylephrine was demonstrated by different studies like 20:1[6], 11:3[17] comparing 5µg, 6µg, 8µg and 9µg against 100µg of phenylephrine. In all the studies, norepinephrine was depicted as effective as phenylephrine in managing maternal hypotension after spinal anaesthesia without any detrimental effects on foetus and mother. Onwochei et al. determined the ED 90 dose of norepinephrine through an up-down sequential allocation study to be 5.8 µg to prevent and treat post-spinal maternal hypotension. While Ngan Kee in a recently published study justified 8µg dose of norepinephrine through a random allocation graded dose response study.[20,21] Difference between two remained by Onwochei et al primarily used norepinephrine to prevent whereas Ngan Kee used it to treat the hypotension.[20,21] We believe, it was reasonable to use norepinephrine in ED 90 dose (6µg) as a prophylactic and treatment which falls within the range of equipotent dose determined by Ngan Kee.[21] Norepinephrine induced vasoconstriction and skin necrosis is another concern for its use in peripheral veins as bolus. But similar risks would remain when diluted solutions of norepinephrine are used equivalent to vasoconstrictor potency of phenylephrine in commonly used concentrations. [6,7,20,21]

**Conclusion**

Norepinephrine is as effective as phenylephrine for maintenance of blood pressure during spinal anaesthesia for caesarean delivery with stable cardiac output and heart rate. It can be used as an alternative vasopressor to phenylephrine for managing intra operative hypotension during spinal anaesthesia for caesarean delivery.

**Reference**


17. Mohta M, Dubey M, Malhotra RK, Tyagi A. Comparison of the potency of phenylephrine and norepinephrine bolus doses used to treat post-spinal


